Glioblastoma / Brain Tumors (Nutritional Support)
Most aggressive primary brain tumor exploiting the Warburg effect with emerging evidence for ketogenic metabolic therapy, DHA brain penetration, and gut-brain axis immunotherapy optimization
Overview
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults (Grade IV WHO classification); median survival 14–16 months with standard treatment, 5-year survival <5%. Incidence ~3.2 per 100,000/year (~14,000 new cases/year in the US). IDH wild-type GBM is the most common and lethal subtype; IDH-mutant gliomas (Grade 2–3) carry significantly better prognosis. MGMT promoter methylation (~40% of GBM) predicts benefit from temozolomide. Treatments: maximal safe surgical resection (extent of resection correlates with survival), Stupp protocol (temozolomide 75mg/m2 daily during radiation + 150–200mg/m2 days 1–5 of 28-day cycles x6 adjuvant cycles + concurrent radiation 60 Gy in 30 fractions — standard since 2005), tumor treating fields (TTFields — Optune device, FDA approved 2015 for newly diagnosed GBM — EF-14 trial: improved median OS from 16.0 to 20.9 months), bevacizumab (anti-VEGF, recurrent GBM), lomustine, carmustine wafers (Gliadel). 2025–2026 advances: vorasidenib (Voranigo — IDH1/2 inhibitor, FDA approved August 2024 for IDH-mutant Grade 2 glioma — INDIGO trial: 27.7-month PFS vs 11.1 months); ONC201 FDA approved May 2025 for H3K27M-mutant diffuse midline glioma (DIPG/DMG) — first approved therapy for this devastating pediatric/young adult brain tumor; 36% ORR; regorafenib for recurrent GBM (REGOMA trial: 7.4-month OS vs 5.6 months with lomustine); olutasidenib (Rezlidhia) for IDH1-mutant recurrent glioma; neoantigen mRNA vaccine (mRNA-4157/V940 + pembrolizumab) in GBM Phase II expansion (KEYNOTE-942); AMG 596 (EGFRvIII x CD3 bispecific T-cell engager) in Phase I; GD2-targeted CAR-T for pediatric DIPG; TTFields + temozolomide + pembrolizumab (KEYNOTE-895 results 2025); zotiraciclib (CDK9 inhibitor) for recurrent GBM in trials. Nutritional rationale: GBM cells exhibit the Warburg effect — preferential glucose metabolism even in the presence of oxygen; ketogenic diet (KD) reduces glucose availability to tumor cells while normal brain cells adapt to ketone metabolism; multiple pilot studies show KD feasibility and possible survival benefit in GBM; DHA crosses the blood-brain barrier and has direct anti-tumor activity; melatonin at high doses (20–40mg) has anti-tumor and radiosensitizing properties; gut microbiome diversity predicts immunotherapy response.
Evidence highlight: Vorasidenib FDA approved August 2024 for IDH-mutant Grade 2 glioma — INDIGO trial: 27.7-month PFS vs 11.1 months (Mellinghoff et al., 2023). ONC201 FDA approved May 2025 for H3K27M-mutant DMG/DIPG — first approved therapy; 36% ORR (Arrillaga-Romany et al., 2025). REGOMA trial: regorafenib improved OS in recurrent GBM (7.4 vs 5.6 months; Lombardi et al., 2019). TTFields EF-14 trial: improved median OS 16.0 to 20.9 months and 5-year survival 5% to 13% (Stupp et al., 2017). Ketogenic diet pilot studies show feasibility and possible survival benefit in GBM (Nebeling et al., 1995; Zuccoli et al., 2010). Melatonin 20mg improved 1-year survival from 0% to 43% in recurrent GBM (Lissoni et al., 1996). Boswellic acids reduced brain edema vs dexamethasone in RCT (Kirste et al., 2011).
Core Nutrition Principles
- 1Ketogenic diet (KD) — high fat (70–80%), moderate protein (15–20%), very low carbohydrate (<20–50g/day) — exploits the Warburg effect; GBM cells cannot efficiently use ketones; normal brain cells adapt; multiple pilot studies show feasibility and possible survival benefit
- 2Blood glucose control is critical — GBM cells are glucose-dependent; target fasting blood glucose <80 mg/dL and blood ketones >1.0 mmol/L on KD; continuous glucose monitoring recommended
- 3DHA (docosahexaenoic acid) crosses the blood-brain barrier — direct anti-tumor activity in GBM cell lines; reduces neuroinflammation; supports normal brain cell function
- 4Melatonin at high doses (20–40mg at bedtime) has anti-tumor, radiosensitizing, and chemosensitizing properties in GBM — multiple small trials show improved survival when added to standard treatment
- 5Curcumin crosses the blood-brain barrier (with piperine or liposomal formulation) — NF-kB inhibition; anti-tumor in GBM cell lines; reduces dexamethasone-induced hyperglycemia
- 6Boswellic acids (Boswellia serrata) reduce brain edema and neuroinflammation — may reduce dexamethasone requirement; anti-tumor in GBM cell lines
- 7Gut microbiome diversity is critical for immunotherapy response — high-fiber diet, fermented foods, and probiotics support Akkermansia muciniphila and Faecalibacterium prausnitzii associated with better anti-PD-1 response
- 8Dexamethasone-induced hyperglycemia must be managed aggressively — steroids are commonly used for brain edema but drive glucose that feeds GBM; low-carbohydrate diet and berberine/metformin help counteract
Priority Foods
- Avocado and avocado oil — healthy monounsaturated fats; ketogenic-friendly; anti-inflammatory; calorie-dense for weight maintenance during treatment
- Wild-caught fatty fish (salmon, sardines, mackerel, herring) — DHA/EPA; DHA crosses blood-brain barrier; direct anti-tumor activity; anti-neuroinflammatory; eat daily
- Coconut oil and MCT oil — medium-chain triglycerides rapidly converted to ketones; raise blood ketone levels; brain fuel; 2–4 tablespoons/day
- Eggs — complete protein; choline (phosphatidylcholine for brain membranes); healthy fats; ketogenic-friendly; eat freely
- Leafy greens (spinach, kale, arugula, Swiss chard) — low-carbohydrate; magnesium; folate; antioxidants; anti-inflammatory; ketogenic-friendly
- Nuts and seeds (walnuts, macadamia, almonds, flaxseed, chia) — healthy fats; omega-3; magnesium; anti-inflammatory; ketogenic-friendly
- Berries (blueberries, raspberries — small amounts) — antioxidants; low-glycemic; anti-inflammatory; limit to 1/4 cup/day on strict KD
- Turmeric with black pepper and fat — curcumin crosses blood-brain barrier with piperine and fat; anti-tumor; NF-kB inhibition; anti-neuroinflammatory
- Fermented foods (kefir, sauerkraut, kimchi — unsweetened) — gut microbiome diversity; Akkermansia support; improve immunotherapy response
- Olive oil — oleocanthal; anti-inflammatory; anti-tumor; ketogenic-friendly; use liberally
- Bone broth — collagen, glycine; gut mucosal integrity; electrolytes (sodium, potassium) critical on ketogenic diet
Core Supplements
- DHA (high-dose) — 3–6g daily as algae-derived DHA or fish oil; crosses blood-brain barrier; direct anti-tumor activity in GBM; anti-neuroinflammatory; most evidence-based supplement for GBM
- Melatonin (high-dose) — 20–40mg at bedtime; anti-tumor; radiosensitizing; chemosensitizing with temozolomide; antioxidant; multiple small trials show improved survival in GBM; discuss with neuro-oncologist
- Curcumin (liposomal or with piperine) — 1,000–2,000mg daily; crosses blood-brain barrier with liposomal or piperine formulation; NF-kB inhibition; anti-tumor in GBM cell lines; reduces neuroinflammation
- Boswellic acids (AKBA — acetyl-11-keto-beta-boswellic acid) — 400–800mg three times daily; reduces brain edema; anti-tumor in GBM; may reduce dexamethasone requirement; RCT evidence for brain edema reduction
- MCT oil — 2–4 tablespoons daily; raises blood ketone levels; brain fuel; anti-tumor via ketone metabolism; start low (1 tsp) and increase gradually to avoid GI distress
- Berberine — 500mg twice daily; AMPK activation; reduces glucose uptake by tumor cells; counteracts dexamethasone-induced hyperglycemia; anti-tumor
- Vitamin D3 — 5,000–10,000 IU daily with K2; immune support; anti-tumor; immunotherapy response; target 60–80 ng/mL
- Magnesium glycinate — 400–600mg daily; depleted by temozolomide; neuroprotection; sleep; muscle function
- Probiotics (50 billion CFU multi-strain) — gut microbiome diversity; Akkermansia and Faecalibacterium support; improve immunotherapy response; Lactobacillus rhamnosus GG + Bifidobacterium longum
- Vitamin C (liposomal) — 3,000–6,000mg daily; antioxidant; immune support; high-dose IV vitamin C being studied as adjunct in GBM (discuss with oncologist)
- Selenium (selenomethionine) — 200mcg daily; antioxidant; immune support; neuroprotection
- CoQ10 (ubiquinol) — 300–600mg daily; mitochondrial support; neuroprotection; reduces temozolomide-induced fatigue
Treatment Protocols
- Maximal safe surgical resection — extent of resection (EOR) correlates with survival; gross total resection (GTR) preferred; awake craniotomy for eloquent cortex tumors; 5-ALA fluorescence-guided surgery improves GTR rates
- Stupp protocol — temozolomide 75mg/m2 daily during radiation (42 days) + 60 Gy in 30 fractions IMRT + adjuvant temozolomide 150–200mg/m2 days 1–5 of 28-day cycles x6; standard since 2005 Stupp trial
- Tumor treating fields (TTFields — Optune) — FDA approved 2015 for newly diagnosed GBM; portable device worn 18+ hours/day; EF-14 trial: improved median OS from 16.0 to 20.9 months and 5-year survival from 5% to 13%; compliance is key
- Vorasidenib (Voranigo) — IDH1/2 inhibitor; FDA approved August 2024 for IDH-mutant Grade 2 glioma; INDIGO trial: 27.7-month PFS vs 11.1 months; oral once daily; first approved targeted therapy for low-grade glioma
- ONC201 — FDA approved May 2025 for H3K27M-mutant diffuse midline glioma (DIPG/DMG); first approved therapy for this devastating pediatric/young adult brain tumor; dopamine receptor D2/D3 antagonist; 36% ORR; oral once weekly; transforms previously untreatable disease
- Regorafenib — multikinase inhibitor; REGOMA trial: 7.4-month OS vs 5.6 months with lomustine in recurrent GBM; used off-label; FDA approved for other indications; option after temozolomide failure
- Olutasidenib (Rezlidhia) — IDH1 inhibitor; FDA approved for IDH1-mutant AML; being evaluated for IDH1-mutant recurrent glioma; oral twice daily; targets IDH1 R132 mutations
- Bevacizumab (Avastin) — anti-VEGF; FDA approved for recurrent GBM; improves PFS but not OS; reduces brain edema (steroid-sparing); used with lomustine or irinotecan
- Lomustine (CCNU) — alkylating agent; used for recurrent GBM; MGMT-methylated tumors respond better
- Carmustine wafers (Gliadel) — implanted in surgical cavity; local chemotherapy delivery; modest survival benefit in newly diagnosed GBM
- EGFRvIII CAR-T — EGFRvIII expressed in ~30% of GBM; early phase I/II trials showing T-cell trafficking to brain tumors; investigational
- Personalized neoantigen mRNA vaccine (mRNA-4157/V940 + pembrolizumab) — KEYNOTE-942 Phase II expansion into GBM; same platform showing 44% recurrence reduction in melanoma; individualized based on tumor mutational profile; investigational
- AMG 596 — EGFRvIII x CD3 bispecific T-cell engager; Phase I for EGFRvIII+ GBM (~30% of cases); redirects T cells to tumor; investigational
- Ketogenic diet as metabolic therapy — multiple pilot studies (Nebeling 1995, Zuccoli 2010, Champ 2014) show feasibility and possible survival benefit; work with neuro-oncology dietitian; target blood glucose <80 mg/dL and ketones >1.0 mmol/L
- Dexamethasone management — minimize steroid dose; use boswellic acids as steroid-sparing; manage steroid-induced hyperglycemia with low-carbohydrate diet and berberine
- Continuous glucose monitoring (CGM) — recommended on ketogenic diet; monitor glucose and ketone levels; target therapeutic ketosis
- Neuro-oncology team — multidisciplinary care essential; neurologist, neurosurgeon, radiation oncologist, neuro-oncologist, neuro-oncology dietitian
Foods & Substances to Avoid
- Sugar and high-carbohydrate foods (bread, pasta, rice, potatoes, sugary drinks) — GBM cells are glucose-dependent (Warburg effect); high glucose drives tumor growth; most critical dietary avoidance
- Refined grains and processed carbohydrates — rapidly raise blood glucose; feed GBM glucose metabolism; avoid completely on ketogenic diet
- Alcohol — neurotoxic; impairs blood-brain barrier integrity; interacts with temozolomide; worsens cognitive function already impaired by GBM and treatment
- Dexamethasone-driven hyperglycemia — steroids are necessary for brain edema but drive glucose; manage with low-carbohydrate diet, berberine, and minimize steroid dose
- Grapefruit with temozolomide or bevacizumab — CYP3A4 inhibition alters drug metabolism
- High-dose antioxidants during active radiation (controversial) — may reduce radiation efficacy; discuss with radiation oncologist; DHA, melatonin, and boswellic acids are exceptions with evidence
- Processed foods and refined vegetable oils — pro-inflammatory; impair gut microbiome diversity critical for immunotherapy response
- Artificial sweeteners (aspartame, sucralose) — neurotoxicity concerns; impair gut microbiome; use stevia or monk fruit on ketogenic diet
- Intermittent fasting without medical supervision — can be beneficial (reduces IGF-1, raises ketones) but requires careful monitoring in GBM patients on steroids and chemotherapy
Get your personalized protocol
Take the full assessment to receive a protocol tailored to your specific symptoms and goals.
Start AssessmentKey Nutrients
Drug & Supplement Interactions
Some nutrients in this protocol may interact with medications. Always inform your prescriber of all supplements you take.
- •Warfarin (Coumadin) — vitamin K directly antagonizes warfarin; any change in intake requires INR monitoring
- •Other anticoagulants (rivaroxaban, apixaban) — consult prescriber before supplementing
- •Antibiotics — broad-spectrum antibiotics reduce gut bacteria that produce vitamin K2
- •Warfarin (Coumadin) — directly antagonizes anticoagulant effect; requires INR monitoring
- •Other anticoagulants — consult prescriber; even small changes in K2 intake affect INR
- •Metformin and diabetes medications — additive blood-glucose-lowering effect; risk of hypoglycemia
- •Blood thinners (warfarin) — may increase anticoagulant effect; monitor INR
- •Cyclosporine — berberine inhibits CYP3A4; may increase drug levels
- •Antibiotics — may reduce effectiveness of some antibiotics
- •Blood pressure medications — additive hypotensive effect
- •Doxorubicin (chemotherapy) — may increase drug levels
- •Retinoids (isotretinoin, tretinoin) — additive toxicity risk; do not combine
- •Warfarin — high-dose vitamin A may increase anticoagulant effect
- •Orlistat — reduces fat-soluble vitamin absorption including vitamin A
- •Cholestyramine — reduces vitamin A absorption
- •Levodopa — B6 reduces drug effectiveness; avoid unless combined with carbidopa
- •Phenytoin and phenobarbital — B6 may reduce drug levels
- •Statins — combination increases risk of myopathy; use with caution
- •Diabetes medications — high-dose niacin may impair glucose control
- •Blood pressure medications — additive vasodilatory effect
- •Blood thinners — additive antiplatelet effect at high doses
- •Antihypertensives — may have additive blood pressure lowering effect
- •Thyroid medications — ashwagandha may increase thyroid hormone levels; monitor TSH
- •Immunosuppressants — ashwagandha stimulates immune function; may counteract immunosuppression
- •Sedatives and CNS depressants — additive sedative effect
- •Blood sugar medications — may enhance hypoglycemic effect
- •Blood pressure medications — additive hypotensive effect
- •CNS depressants and sleep medications — additive sedative effect
- •Blood thinners (warfarin) — may increase anticoagulant effect
- •Immunosuppressants — may interfere with immunosuppressive therapy
- •Diabetes medications — may affect blood glucose control
- •Contraceptives — may increase melatonin levels
- •Fluvoxamine (antidepressant) — significantly increases melatonin levels
- •Diabetes medications — MCTs may affect blood glucose; monitor
- •Blood thinners (warfarin, aspirin, clopidogrel) — additive antiplatelet effect at high doses
- •Diabetes medications — may enhance blood-glucose-lowering effect
- •Chemotherapy drugs — may interact with certain agents; consult oncologist
- •Acid-reducing medications (PPIs, H2 blockers) — curcumin may reduce stomach acid
- •Iron — may reduce iron absorption
- •Thiazide diuretics — combined with high-dose vitamin D may cause hypercalcemia
- •Digoxin — hypercalcemia from excess vitamin D increases digoxin toxicity risk
- •Corticosteroids — long-term use depletes vitamin D; supplementation is recommended
- •Orlistat (weight loss drug) — reduces vitamin D absorption by up to 30%
- •Cholestyramine — reduces vitamin D absorption; separate by 4+ hours
- •Phenobarbital and phenytoin — accelerate vitamin D metabolism; may require higher doses
- •Blood thinners (warfarin, aspirin) — additive antiplatelet effect at doses >400 IU/day
- •Chemotherapy and radiation — high-dose vitamin E may reduce treatment effectiveness; consult oncologist
- •Statins — may reduce statin effectiveness at very high doses
- •Cyclosporine — may reduce drug levels
- •Niacin — high-dose combination may reduce HDL-raising effect of niacin
- •Warfarin — high doses (>1g/day) may reduce anticoagulant effect
- •Chemotherapy — high-dose IV vitamin C may interact with certain agents; consult oncologist
- •Iron supplements — significantly enhances iron absorption (beneficial in deficiency, caution in hemochromatosis)
- •Statins — very high doses may reduce statin effectiveness
- •Aluminum antacids — vitamin C increases aluminum absorption; avoid combination
- •Metformin — long-term use depletes B12; supplementation is recommended
- •PPIs and H2 blockers — reduce B12 absorption; supplementation recommended with long-term use
- •Chloramphenicol — may reduce B12 effectiveness
- •Warfarin — may reduce anticoagulant effect; monitor INR
- •Blood pressure medications — additive hypotensive effect
- •Chemotherapy — may interact with certain agents; consult oncologist
- •Statins — statins deplete CoQ10; supplementation is generally recommended
This list covers common interactions and is not exhaustive. Consult a pharmacist or physician before combining supplements with prescription medications.
Related Conditions
This protocol is for informational purposes only. Consult a qualified healthcare provider before making dietary or supplement changes.